Fluorofenidone inhibits TGF-β1 induced CTGF via MAPK pathways in mouse mesangial cells

Pharmazie

Volumn 64, Issue 10, 2009, Pages 680-684

  Wang, Ling ^a   Hu, Gao Yun ^b   Shen, Hong ^a   Peng, Zhang Zhe ^a   Ning, Wang Bin ^a   Tao, Li Jian ^a,c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c State Key Laboratory of Medical Genetics of China   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTIFIBROTIC AGENT; CONNECTIVE TISSUE GROWTH FACTOR; FLUOROFENIDONE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PYRIDINE DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; 5 METHYL 1 (3 FLUOROPHENYL) 2 (1H) PYRIDONE; 5-METHYL-1-(3-FLUOROPHENYL)-2-(1H)-PYRIDONE; CTGF PROTEIN, MOUSE; FIBRINOLYTIC AGENT; MESSENGER RNA; PYRIDONE DERIVATIVE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; MESANGIUM CELL; MOUSE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; BLOTTING, WESTERN; CONNECTIVE TISSUE GROWTH FACTOR; DOWN-REGULATION; FIBRINOLYTIC AGENTS; MESANGIAL CELLS; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDONES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA1;

EID: 74949117456     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2009.9525     Document Type: Article

References (34)

1. Ahn JD, Morishita R, Kaneda Y Kim HJ, Kim YD, Lee HJ, Lee KU, Park JY, Kim YH, Park KK, Chang YC, Yoon KH, Kwon HS, Park KG, Lee IK (2004) Transcription factor decoy for AP-1 reduces mesangial cell proliferation and extracellular matrix production in vitro and in vivo. Gene Therapy 11: 916-923.
2. Buschhausen L, Seibold S, Gross O, Matthaeus T, Weber M, Schulze-Lohoff E (2001) Regulation of mesangial cell function by vasodilatory signaling molecules. Cardiovasc Res 51 : 463-469.
3. Cao W, He L, Liu W, Huang Z, Cheng Z. (2006) Determination of AKFPD in whole blood of rat by HPLC-UV. J Chromatogr B Analyt Technol Biomed Life Sci. 833: 257-259.
4. Ceol M, Gambaro G, Sauer U, Baggio B, Anglani F, Forino M, Facchin S, Bordin L, Weigert C, Nerlich A, Schleicher ED (2000) Glycosaminoglycan therapy prevents TGF-ß1 overexpression and pathologic changes in renal tissue of long-term diabetic rats. J Am Soc Nephrol 11: 2324-2336.
5. Cernuda-Morollón E, Rodríguez-Pascual F, Klatt P, Lamas S, Pérez-Sala D (2002) PPAR agonists amplify iNOS expression while inhibiting NF-B: implications for mesangial cell activation by cytokines. J Am Soc Nephrol 13 : 2223-2231.
6. Chin BY, Petrache I, Choi AM, Choi AE. (1999) Transforming growth factor beta1 rescues serum deprivation-induced apoptosis via the mitogen-activated protein kinase (MAPK) pathway in macrophages. J Biol Chem 274: 11362-11368.
7. Cho ME, Smith DC, Branton MH, Penzak SR, Kopp JB (2007) Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2: 906-913.
8. Cuschieri J, Maier RV (2005) Mitogen-activated protein kinase (MAPK). Crit Care Med 33: S417-S419.
9. Di Sario A, Bendia E, Macarri G Candelaresi C, Taffetani S, Marzioni M, Omenetti A, De Minicis S, Trozzi L, Benedetti A. (2004) The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1(I), TIMP-1 and MMP-2. Dig Liver Dis 36: 744-751.
10. El Nahas AM, Muchaneta-Kubara EC, Essawy M, Soylemezoglu O (1997) Renal fibrosis: insights into pathogenesis and treatment. Int J Biochem Cell Biol 29: 55-62.
11. Hewitson TD, Kelynack KJ, Tait MG Martic M, Jones CL, Margolin SB, Becker GJ (2001) Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis. J Nephrol 14: 453-460.
12. Hommes DW, Peppelenbosch MP, van Deventer SJ (2003) Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets. Gut 52: 144-51.
13. Ikawa Y, Ng PS, Endo K, Kondo M, Chujo S, Ishida W, Shirasaki F, Fujimoto M, Takehara K (2008) Neutralizing monoclonal antibody to human connective tissue growth factor ameliorates transforming growth factor-beta-induced mouse fibrosis. J Cell Physiol 216: 680-687.
14. Kikkawa R, Koya D, Haneda M (2003) Progression of diabetic nephropathy. Am J Kidney Dis 41: S19-S21.
15. Kopp JB, Factor VM, Mozes M Nagy P, Sanderson N, Böttinger EP, Klotman PE, Thorgeirsson SS (1996) Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest 74: 991-1003.
16. Kyriakis JM, Avruch J (2001) Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81: 807-869.
17. Liu Y (2006) Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 69: 213-217.
18. Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM, Brown L. (2001) Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol 133: 687-694.
19. Moritani NH, Kubota S, Eguchi T Fukunaga T, Yamashiro T, Takano-Yamamoto T, Tahara H, Ohyama K, Sugahara T, Takigawa M (2003) Interaction of AP-1 and the ctgf gene: a possible driver of chondrocyte hypertrophy in growth cartilage. J Bone Miner Metab 21: 205-210.
20. Nakayama S, Mukae H, Sakamoto N Kakugawa T, Yoshioka S, Soda H, Oku H, Urata Y, Kondo T, Kubota H, Nagata K, Kohno S (2008) Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts. Life Sci 82: 210-217.
21. Novak J, Vu HL, Novak L Julian BA, Mestecky J, Tomana M. (2002) Interactions of human mesangial cells with IgA and IgA-containing immune complexes. Kidney Int 62: 465-475.
22. Okada H, Kikuta T, Kobayashi T Inoue T, Kanno Y, Takigawa M, Sugaya T, Kopp JB, Suzuki H (2005) Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. J Am Soc Nephrol 16: 133-143.
23. Ouyang X, Jessen WJ, Al-Ahmadie H, Serio AM, Lin Y, Shih WJ, Reuter VE, Scardino PT, Shen MM, Aronow BJ, Vickers AJ, Gerald WL, Abate-Shen C (2008) Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer. Cancer Res. 68: 2132-2144.
24. Ozes ON et al. (2006) Pirfenidone attenuates transforming growth factor-beta-induced activation of P38-alpha and P38-gamma mitogen-activated protein kinases in human lung fibroblasts: Implications for treatment of fibrotic lung diseases. Slide Presentations from CHEST Tuesday, October 24.
25. Qi W, Twigg S, Chen X, Polhill TS, Poronnik P, Gilbert RE, Pollock CA (2005) Integrated actions of transforming growth factor-1 and connective tissue growth factor in renal fibrosis. Am J Physiol Renal Physiol 288: F800-F809.
26. Sakharova OV, Taal MW, Brenner BM (2001) Pathogenesis of diabetic nephropathy: focus on transforming growth factor-beta and connective tissue growth factor. Curr Opin Nephrol Hypertens 10: 727-738.
27. Schnaper WH, Hayashida T, Hubchak SC, Poncelet AC (2003) TGF-signal transduction and mesangial cell fibrogenesis. Am J Physiol Renal Physiol 284: F243-F252.
28. Shen H, Fan Y, Yang X, Burczynski FJ, Li P, Gong Y (2005) Increased expression of cystic fibrosis transmembrane conductance regulator in rat liver after common bile duct ligation. J Cell Physiol 203: 599-603.
29. Tao LJ, Zhang J, Hu GY. (2004) Effects of 1-(3-fluorophenyl)-5-methyl-2- (1H)-pyridone on renal fibroblast in rats: Zhong Nan Da Xue Xue Bao Yi Xue Ban., Apr 29 (2): 139-141.
30. Van Erp C, Irwin NG, Hoey AJ (2006) Long-term administration of pirfenidone improves cardiac function in mdx mice. Muscle Nerve 34: 327-334.
31. Weigert C, Sauer U, Bodbeck K Pfeiffer A, Häring HU, Schleicher ED (2000) AP-1 proteins mediate hyperglycemia-induced activation of the human TGF-ß1 promoter in mesangial cells. J Am Soc Nephrol 11: 2007-2016.
32. Wolf G (2006) Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway. Kidney Int 70: 1914-1919.
33. Xiao YQ, Malcolm K, Worthen GS, Gardai S, Schiemann WP, Fadok VA, Bratton DL, Henson PM (2002) Cross-talk between ERK and p38 MAPK mediates selective suppression of pro-inflammatory cytokines by transforming growth factor-beta. J Biol Chem 277: 14884-14893.
34. Zhao Q, Chen N, Wang WM, Lu J, Dai BB (2004) Effect of transforming growth factor-beta on activity of connective tissue growth factor gene promoter in mouse NIH/3T3 fibroblasts. Acta Pharmacol Sin 25: 485-489.